{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:18:37Z","timestamp":1783657117387,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from the background population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In nationwide Danish registries we identified female patients treated with bromocriptine in the period 1995\u20132018. Patients were included at date of second redeemed prescription and were matched 1:5 with controls from the background population based on age, sex and year of inclusion by use of incidence density sampling. The outcomes were hospital admission for or outpatient diagnosis of heart valve disease, and death as competing risk. Incidence rates, cumulative incidence curves, and adjusted cox-proportional hazard models adjusted for cardiovascular risk factors were used to assess outcomes in bromocriptine users versus controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3035 female bromocriptine users and 15,175 matched controls were included. Median age at inclusion was 32\u00a0years (Q1\u2013Q3, 28\u201337\u00a0years). Both bromocriptine users and controls had few comorbidities and low use of concomitant pharmacotherapy. Within 10\u00a0years of follow-up, 11 patients (0.34%, 95% CI 0.13\u20130.55%) and 44 controls (0.29%, 95% CI 0.20\u20130.37) met the primary endpoint of heart valve disease,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.63. The adjusted cox regression analysis yielded a hazard ratio of 0.96 (95% confidence interval (CI) 0.55\u20131.69,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.89).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment initiation with ergot-derived dopamine agonist bromocriptine in younger women with few comorbidities, was associated with a low absolute long-term risk of heart valve disease, not significantly different from the risk in age and sex matched population controls. Thus, indicating a low clinical yield of pre-treatment echocardiographic screening in this patient population in accordance with current guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-021-02439-y","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T04:02:33Z","timestamp":1640664153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine"],"prefix":"10.1186","volume":"21","author":[{"given":"Marianne F.","family":"Clausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"R\u00f8rth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Malta","family":"Westergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Weeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Fosb\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lund","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"issue":"2","key":"2439_CR1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","volume":"132","author":"JD Hutcheson","year":"2011","unstructured":"Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease\u2013it was meant 2B. Pharmacol Ther. 2011;132(2):146\u201357.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2439_CR2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/cvr\/cvx092","volume":"113","author":"E Goldberg","year":"2017","unstructured":"Goldberg E, Grau JB, Fortier JH, Salvati E, Levy RJ, Ferrari G. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovasc Res. 2017;113(8):849\u201357.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"2439_CR3","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93(9):3348\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2439_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"J Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10(6):334\u20136.","journal-title":"Cardiol Rev"},{"issue":"3","key":"2439_CR5","first-page":"340","volume":"33","author":"S Yarman","year":"2012","unstructured":"Yarman S, Kurtulmus N, Bilge A. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Neuro Endocrinol Lett. 2012;33(3):340\u20136.","journal-title":"Neuro Endocrinol Lett"},{"issue":"8","key":"2439_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"T Kvernmo","year":"2006","unstructured":"Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28(8):1065\u201378.","journal-title":"Clin Ther"},{"issue":"4","key":"2439_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1517\/14740338.2016.1151493","volume":"15","author":"RS Auriemma","year":"2016","unstructured":"Auriemma RS, Grasso LF, Pivonello R, Colao A. The safety of treatments for prolactinomas. Expert Opin Drug Saf. 2016;15(4):503\u201312.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2439_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","volume":"35","author":"G Trifiro","year":"2012","unstructured":"Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35(2):159\u201371.","journal-title":"Drug Saf"},{"issue":"7","key":"2439_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","volume":"31","author":"A Capozzi","year":"2015","unstructured":"Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506\u201310.","journal-title":"Gynecol Endocrinol"},{"key":"2439_CR10","doi-asserted-by":"crossref","unstructured":"Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Early (Uncomplicated) Parkinson's Disease. European Handbook of Neurological Management, Volume 1, Second EditionSep. 2010.","DOI":"10.1002\/9781444328394.ch14"},{"issue":"3","key":"2439_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1715163514529740","volume":"147","author":"T Patel","year":"2014","unstructured":"Patel T, Chang F. Parkinson\u2019s disease guidelines for pharmacists. Can Pharm J (Ott). 2014;147(3):161\u201370.","journal-title":"Can Pharm J (Ott)"},{"issue":"2","key":"2439_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2439_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","volume":"15","author":"CL Boguszewski","year":"2012","unstructured":"Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44\u20139.","journal-title":"Pituitary"},{"issue":"1","key":"2439_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-12-0121","volume":"167","author":"A Elenkova","year":"2012","unstructured":"Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167(1):17\u201325.","journal-title":"Eur J Endocrinol"},{"key":"2439_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"2439_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38\u201341.","journal-title":"Scand J Public Health"},{"issue":"7 Suppl","key":"2439_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22\u20135.","journal-title":"Scand J Public Health"},{"key":"2439_CR18","doi-asserted-by":"crossref","unstructured":"Arasho BD, Schaller B, Sandu N, Zenebe G. Gender-related differences in pituitary adenomas. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2009;117(10):567\u201372.","DOI":"10.1055\/s-0029-1202831"},{"issue":"9689","key":"2439_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","volume":"374","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet (London, England). 2009;374(9689):577\u201385.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2439_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/jc.2013-2254","volume":"99","author":"WM Drake","year":"2014","unstructured":"Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2439_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2265.2012.04349.x","volume":"77","author":"I Halperin","year":"2012","unstructured":"Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol. 2012;77(2):275\u201380.","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2439_CR22","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1210\/jc.2011-3257","volume":"97","author":"C Steffensen","year":"2012","unstructured":"Steffensen C, Maegbaek ML, Laurberg P, Andersen M, Kistorp CM, Norrelund H, et al. Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endocrinol Metab. 2012;97(5):1629\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2439_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1210\/me.2013-1349","volume":"28","author":"RJ Marano","year":"2014","unstructured":"Marano RJ, Ben-Jonathan N. Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol (Baltimore, Md). 2014;28(5):622\u201333.","journal-title":"Mol Endocrinol (Baltimore, Md)"},{"issue":"18","key":"2439_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/eurheartj\/ehs233","volume":"35","author":"R Haring","year":"2014","unstructured":"Haring R, Friedrich N, Volzke H, Vasan RS, Felix SB, Dorr M, et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2014;35(18):1215\u201321.","journal-title":"Eur Heart J"},{"issue":"6","key":"2439_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","volume":"49","author":"J Krogh","year":"2017","unstructured":"Krogh J, Selmer C, Torp-Pedersen C, Gislason GH, Kistorp C. Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Hormone Metab Res. 2017;49(6):411\u20137.","journal-title":"Hormone Metab Res"},{"issue":"6","key":"2439_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","volume":"83","author":"JP Singh","year":"1999","unstructured":"Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897\u2013902.","journal-title":"Am J Cardiol"},{"issue":"3","key":"2439_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/0002-8703(89)90739-4","volume":"117","author":"CY Choong","year":"1989","unstructured":"Choong CY, Abascal VM, Weyman J, Levine RA, Gentile F, Thomas JD, et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J. 1989;117(3):636\u201342.","journal-title":"Am Heart J"},{"issue":"9540","key":"2439_CR28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet (London, England). 2006;368(9540):1005\u201311.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2439_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.echo.2007.05.006","volume":"21","author":"G Stefano","year":"2008","unstructured":"Stefano G, Fox K, Schluchter M, Hoit BD. Prevalence of unsuspected and significant mitral and aortic regurgitation. J Am Soc Echocardiogr. 2008;21(1):38\u201342.","journal-title":"J Am Soc Echocardiogr"},{"key":"2439_CR30","volume-title":"Principles and practice of screening for disease","author":"JMG Wilson","year":"1968","unstructured":"Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968."},{"issue":"4","key":"2439_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/BLT.07.050112","volume":"86","author":"A Andermann","year":"2008","unstructured":"Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317\u20139.","journal-title":"Bull World Health Organ"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02439-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T04:02:59Z","timestamp":1640664179000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02439-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02439-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-184426\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the declaration of Helsinki and approved by the Institutional Review Board of the Capital Region of Denmark (approval number: P-2019-348) in accordance with the General Data Protection Regulation. Registry-based studies in which individuals cannot be identified do not require consent from the patients according to national Danish regulations. Data access was obtained through Statistics Denmark, which allows data access upon application for all research institutions based in Denmark. Foreign researchers can get access through an affiliation to a Danish authorized research institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}